Areas of unmet need for DLBCL: primary refractory disease and double-hit lymphoma

(1:9)

The outcomes of patients with primary refractory and relapsed acute leukemia

(1:19)

Therapeutic options for patients with primary refractory/early relapsed DLBCL

(3:27)

Primary refractory young myeloma: a difficult clinical situation

(4:32)

Primary Refractory Acute Myeloid Leukemia

(6:22)

Treatment options for patients with LBCL who relapse or are refractory to initial treatment

(3:4)

Relapsed/Refractory B-cell Lymphomas in the CAR-T Era: Improving Outcomes in a Population at Need

(50:48)

An Operational Definition of Primary Refractory AML: Dr Paul Ferguson at ASH 2015

(4:51)

Outcomes in patients with double refractory DLBCL receiving third-line CD19 CAR-T therapy

(2:9)

Haematology updates | Primary Refractory \u0026 Extramedullary Disease:

(2:5:50)

Defining primary refractory disease and its effect on patient outcomes in DLBCL

(4:14)

Flotetuzumab for primary refractory and early relapsed AML

(1:35)

Debate: Best second line therapy for relapsed Hodgkin lymphoma - Brentuximab alone/+ chemo

(15:4)

Episode 076: Management of primary refractory diffuse large B-cell lymphoma (DLBCL)

(35:56)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

(2:7)

Absolute Refractory period vs Relative refractory period | ARP vs RRP | All-or-Non Law

(5:43)

Satellite Symposium | Sequencing treatment options in primary refractory DLBCL

(17:53)

Patient Success Stories: Primary Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

(10:9)

How Is Relapsed/Refractory DLBCL Treated?

(4:32)

Treatment of Primary Myelofibrosis

(10:42)